Cor Vasa 2014, 56(2):e98-e104 | DOI: 10.1016/j.crvasa.2014.02.002
Residual cardiovascular risk in patients with stable coronary heart disease over the last 16 years (Czech part of the EUROASPIRE I-IV surveys)
- a Centrum preventivní kardiologie, II. interní klinika, Lékařská fakulta Plzeň, Univerzita Karlova v Praze a Fakultní nemocnice Plzeň, Plzeň, Česká republika
- b Centrum kardiovaskulární prevence, 1. lékařská fakulta Univerzity Karlovy a Thomayerova nemocnice, Praha, Česká republika
Introduction: Many patients with coronary heart disease (CHD) who achieve target low density lipoprotein cholesterol (LDL-C) values still experience vascular events because of a residual vascular risk due to other risk factors, particularly non-LDL-C dyslipidemia, because of non-adherence to non-pharmacological and pharmacological management.
Method and aims: We used simple markers and inexpensive screening tools for metabolic disorders associated with insulin resistance and metabolic syndrome identifying subjects at a high cardiovascular (CV) risk - atherogenic dyslipidemia (triglycerides [TG] ≥2.0 mmol/l and high-density lipoprotein cholesterol [HDL-C] ≤1.0 mmol/l in males and ≤1.2 mmol/l in females), hypertriglyceridemic waist (TG ≥2.0 mmol/l and waist circumference ≥90 cm in males and ≥85 cm in females), atherogenic index of plasma (AIP = log [TG/HDL-C]) and non-HDL-C (non-HDL-C = total cholesterol - HDL-C)]. We focused on the development of these risk factors among patients with established stable CHD over more than the last 16 years.
Results: We examined 1 484 patients, 1 152 males (78%) and 332 females (22%) from the Czech parts of EUROASPIRE I-IV (EA I-IV) surveys. In males, TG, HDL-C, and non-HDL-C decreased significantly from EA I to IV (p for trends NS; 0.0001; 0.0001, respectively). In females, there was no change in TG; HDL-C, and non-HDL-C decreased significantly (p for trends NS; 0.03; 0.0001, respectively). Atherogenic dyslipidemia prevalence decreased significantly in both sexes (p for trends 0.004 and 0.0012, respectively). Hypertriglyceridemic waist prevalence showed no change in either sex. There were no significant changes in AIP risk strata in either sex. About 30-40% of males and 24-30% of females had their AIP in the high-risk strata, which tended to increase in males. The prevalence of type 2 diabetes (T2DM) and waist circumference increased significantly from EAI to IV (from 23% to 48%, and from 98 cm to 105 cm, respectively; both p for trend
Keywords: Atherogenic dyslipidemia; Atherogenic index of plasma; Glucose metabolism disorders; Hypertriglyceridemic waist; Residual vascular risk; Stable coronary heart disease
Received: January 15, 2014; Accepted: February 3, 2014; Published: April 1, 2014 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- www.who.int
- EUROASPIRE Study Group, EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease. Principal results, European Heart Journal 18 (1997) 1569-1582.
Go to original source...
Go to PubMed...
- EUROASPIRE II Group, Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II, European Heart Journal 22 (2001) 554-572.
Go to original source...
Go to PubMed...
- K. Kotseva, D. Wood, G. De Backer, et al.; for the EUROASPIRE Study Group, EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries, European Journal of Cardiovascular Prevention and Rehabilitation 17 (2010) 530-540.
Go to original source...
Go to PubMed...
- http://www.escardio.org/guidelines-surveys/eorp/prevention-registries/Pages/euroaspire-iv.aspx
- J.C. Fruchart, F.M. Sacks, M.P. Hermans, et al., The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients, Diabetes and Vascular Disease Research 5 (2008) 319-335.
Go to original source...
Go to PubMed...
- Cholesterol Treatment Trialists' (CTT) Collaborators, P.M. Kearney, L. Blackwell, R. Collins, et al., Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet 371 (2008) 117-125.
Go to original source...
Go to PubMed...
- O. Mayer Jr, J. Bruthans, K. Timoracká, on behalf of Czech EUROASPIRE I-IV investigators, The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study, Cor et Vasa 56 (2014) e91-e97.
Go to original source...
- Ústav zdravotnických informací a statistiky: Zdravotnická ročenka ČR 2011; http://www.uzis.cz
- K.G. Alberti, R.H. Eckel, S.M. Grundy, et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation 120 (2009) 1640-1645.
Go to original source...
Go to PubMed...
- I. Lemieux, A. Pascot, C. Couillard, et al., Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?, Circulation 102 (2000) 179-184.
Go to original source...
Go to PubMed...
- B.J. Arsenault, I. Lemieux, J.P. Després, et al., The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study, Canadian Medical Association Journal 182 (2010) 1427-1432.
Go to original source...
Go to PubMed...
- S. Klein, D.B. Alliso, S.B. Heymsfield, Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association, American Journal of Clinical Nutrition 85 (2007) 1197-1202.
Go to original source...
Go to PubMed...
- A.L. Catapano, Z. Reiner, G. De Backer, et al., ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Aterosclerosis Society (EAS), Atherosclerosis 217 (2011) 3-46.
Go to original source...
Go to PubMed...
- M. Dobiášová, J. Frohlich, Nový aterogenní index plazmy (AIP) odpovídá poměru triglyceridů a HDL-cholesterolu, velikosti částic lipoproteidů a esterifikační rychlosti cholesterolu: změny po léčbě lipanorem, Vnitřní lékařství 46 (2000) 152-156.
Go to PubMed...
- M. Dobiasova, J. Frohlich, The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in Apo-B-lipoprotein-depleted plasma (FERHDL), Clinical Biochemistry 34 (2001) 583-588.
Go to original source...
Go to PubMed...
- AIP calculator www.biomed.cas.cz/fgu/aip
- G. Hu, P. Jousilahti, Q. Qiao, et al., Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction, Diabetologia 48 (2005) 856-861.
Go to original source...
Go to PubMed...
- M. Bartnik, L. Rydén, R. Ferrari, et al., The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on Diabetes and the Heart, European Heart Journal 25 (2004) 1880-1890.
Go to original source...
Go to PubMed...
- L. Rydén, P.J. Grant, S.D. Anker, et al., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular disease developed in collaboration with EASD, European Heart Journal 34 (2013) 3035-3087.
Go to original source...
Go to PubMed...
- R. Cífková, Z. Škodová, J. Bruthans, et al., Longitudinal trends in the prevalence of the metabolic syndrome in the Czech population from 1997-1998 to 2006-2009. The Czech post-MONICA Study, in: Abstract for the Conference of ECRP, Prague 2010.
- P.M. Ridker, A. Pradhan, J.G. MacFadyen, et al., Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet 380 (2012) 565-571.
Go to original source...
Go to PubMed...
- The ACCORD Study Group, Effects of combination lipid therapy in type 2 diabetes mellitus, New England Journal of Medicine 362 (2010) 1563-1574.
Go to original source...
Go to PubMed...
- The ACCORD Study Group and ACCORD Eye Study Group, Effects of medical therapies on retinopathy progression in type 2 diabetes, New England Journal of Medicine 362 (2010) 1563-1574.
- G. De Bacquer, J. Dallongeville, K. Kotseva, et al, Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE Risk Categories, International Journal of Cardiology 168 (2013) 910-914.
Go to original source...
Go to PubMed...